All About SGLT Inhibitors for T1D

SGLT inhibitors are oral medications that work by decreasing the production of transport proteins and reducing the absorption of glucose by the intestines and kidneys respectively. Up until now, these drugs have been used exclusively by those with Type 2 diabetes. Inhibitors on the market currently include SGLT-2 inhibitors Farxiga and Jardiance, and Zynquista, the first dual SGLT-1 and SGLT-2 inhibitor.

JDRF Launches Center of Excellence to Accelerate Cure for Type 1 Diabetes

On September 4, JDRF announced the launch of its Northern California Center of Excellence, dedicated to focused efforts on research and breakthroughs to cure Type 1 diabetes.

People With Diabetes Forgoing Basic Needs in Order to Survive According to New Studies

According to two studies presented at the American Association of Diabetes Educators 2019 Annual Conference, people with diabetes are forgoing basic needs in the face of rising healthcare costs and taking to underground exchanges of necessary supplies.

Nasal Glucagon Baqsimi Approved by the FDA

On Thursday, the Food and Drug Administration approved Eli Lilly and Company's Baqsimi, a non-injectable, nasal glucagon and the first of its kind.

Senate Bill Aims to Cut Price of Insulin by 75%

The "Insulin Price Reduction Act" would create a new pricing model for insulin, incentivizing manufacturers to lower list prices to 2006 prices.

New Guidance from the US Treasury Opens Door to High Deductible Exemptions for Diabetes Care

The U.S. Treasury issued new guidance which aims to make accessing medications for chronic conditions easier under some insurance plans.

New Senate Bill Would Speed up Availability of Generic Insulin in the U.S.

The Affordable Insulin Approvals Now Act is a bipartisan bill intended to speed up the approval process of generic insulins in order to help lower costs.

Tidepool and Medtronic Announce Collaboration on Interoperable Automated Insulin Pump

Tidepool announced that they have partnered with Medtronic to create an interoperable automated insulin pump system.

FDA Approves First Ready-to-Use Liquid Stable Glucagon Gvoke

On September 10 the FDA approved the Gvoke HypoPen and Gvoke PFS, emergency glucagon rescue devices for the treatment of severe hypoglycemia.

Exciting Trial Results for Tandem’s Control-IQ Hybrid Closed Loop System

Participants using Control-IQ saw an increased time in range, lowered HbA1c, and less time in hyperglycemia and hypoglycemia.

Nonprofits Announce Groundbreaking Research Initiative

The Parker Institute, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust announced a research initiative to study immunotherapy-induced diabetes.

Colorado Becomes First State to Pass Bill Capping Insulin Costs

On Wednesday, May 22, Colorado became the first state in the U.S. to put a price cap on insulin.

FDA Approves New Treatment for Diabetic Retinopathy

Regeneron Pharmaceuticals announced that the FDA has approved EYLEA (aflibercept) to treat all stages of diabetic retinopathy.

Express Scripts Won’t Cover Lilly’s Generic Insulin

The largest PBM in the U.S. recently released a list of formulary exclusions that included 'Insulin Lispro' as an excluded medication.

Previously Healthy from Beyond Type 1 Named Webby People’s Voice Award Winner

Hailed as the “Internet’s highest honor” and “the Oscars of the Internet” The Webby Awards are presented by the International Academy of Digital Arts and Sciences (IADAS) honoring excellence on the Internet.